Sonoma Pharmaceuticals, Inc. (SNOA)
| Market Cap | 5.60M -12.5% |
| Revenue (ttm) | 23.49M +38.7% |
| Net Income | -1.80M |
| EPS | -0.59 |
| Shares Out | 4.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 157,742 |
| Open | 1.260 |
| Previous Close | 1.240 |
| Day's Range | 1.150 - 1.270 |
| 52-Week Range | 0.850 - 3.950 |
| Beta | 1.31 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 10, 2026 |
About SNOA
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial c... [Read more]
Financial Performance
In fiscal year 2026, Sonoma Pharmaceuticals's revenue was $19.53 million, an increase of 36.68% compared to the previous year's $14.29 million. Losses were -$3.18 million, -8.16% less than in 2025.
Financial StatementsNews
Sonoma Pharmaceuticals reports Q1 EPS (9c) vs. (76c) last year
Reports revenue $6.4M vs. $4.02M last year. “Our first quarter results demonstrate that Sonoma has reached an important inflection point,” said Amy Trombly, CEO of Sonoma. “We delivered record quarter...
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
Total revenue increased 60% year over year to $6.4 million Net loss per share decreased 88% compared to the prior-year quarter Gross margin expanded to 40% as operating expenses remained stable FDA cl...
Sonoma Pharmaceuticals receives 510(k) clearance for Microdacyn solution
Sonoma Pharmaceuticals (SNOA) has received a new 510(k) clearance from the U.S. Food and Drug Administration for its Microdacyn Wound Irrigation Solution, including expanded claims, clearance for mult...
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution
BOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced it has received a new 510...
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
Revenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025 United States revenues increased 194% in Q4 2026 compared to Q4 2025 and 117% in FY 2026 compared to FY 20...
Sonoma Pharmaceuticals prices 2.96M shares at $1.35 in public offering
Sonoma Pharmaceuticals (SNOA) announced the pricing of its public offering made on a firm commitment basis with gross proceeds to the Company expected to be approximately $4M, before deducting fees…
Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering
BOULDER, CO / ACCESS Newswire / April 24, 2026 / Sonoma Pharmaceuticals, Inc. (the "Company" or "Sonoma Pharmaceuticals") (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technolo...
Sonoma Pharmaceuticals files to sell units, no amount given
Dawson James Securities is acting as manager.
Sonoma announces U.S. retail launch of advanced burn relief hydrogel
Sonoma Pharmaceuticals (SNOA) announced the U.S. retail launch of its advanced HOCl-based burn relief hydrogel in CVS (CVS) and Walmart (WMT) stores nationwide. The hydrogel is indicated for the manag...
Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart
BOULDER, CO / ACCESS Newswire / March 24, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced the U.S. retail launch o...
Sonoma Pharmaceuticals launches Aquanil AD
Sonoma Pharmaceuticals (SNOA) announced the launch of Aquanil AD, a hypochlorous acid based dermatology product line for sensitive skin, developed exclusively for Persundefinedn & Covey, Inc. for dist...
Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin
BOULDER, CO / ACCESS Newswire / March 18, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlo...
Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results
Revenue increased 22% for the quarter ended December 31, 2025 and 33% for the nine months ended December 31, 2025 compared to prior year Net loss and net loss per share decreased from prior year for b...
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypoch...
Sonoma Pharmaceuticals’ Reliefacyn Advanced receives NRS Seal of Acceptance
Sonoma Pharmaceuticals (SNOA) announced that Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel has earned the National Rosacea Society Seal of Acceptance.
National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced
BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypoc...
Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf
BOULDER, CO / ACCESS Newswire / November 6, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypoch...
Sonoma Pharmaceuticals reports Q2 EPS (32c) vs. (59c) last year
Reports Q2 revenue $5.6M vs. $3.6M last year. “We are thrilled to report the highest quarterly revenues in Sonoma’s history – $5.6 million for the three months ended September 30,…
Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results
Revenues increased 57% for the quarter and 38% for the six months ended September 30, 2025 compared to same periods last year U.S. revenue increased 115% for the quarter and 86% for the six months end...
Sonoma Pharmaceuticals, Medline launch HOCI wound cleanser
Sonoma Pharmaceuticals (SNOA) announced the launch of a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP. The product will be distributed by Medline into hospital systems, hom...
Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals
BOULDER, CO / ACCESS Newswire / October 14, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader in developing and producing stabilized hypochlorous acid (HOCl) products based...
Sonoma Pharmaceuticals lists facial spray under FDA’s MoCRA
Sonoma Pharmaceuticals (SNOA) registered its manufacturing facility and listed its Microcyn-based facial spray under the FDA’s Modernization of Cosmetics Regulation Act of 2022. The MoCRA registration...
Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA
BOULDER, COLORADO / ACCESS Newswire / October 7, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized h...
Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
BOULDER, COLORADO / ACCESS Newswire / September 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilize...
National Psoriasis Foundation Awards Seal of Recognition to Sonoma Pharmaceuticals for Reliefacyn Advanced
BOULDER, CO / ACCESS Newswire / August 26, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochl...